The letter is not standard Asia-Pacific pharmaceutical industry will still be jammed for 3 months

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd., which tried to go public in 2001, after several twists and starts, last November the end of the application was finally approved. However Hormong, because the company information disclosure is extremely insufficient, and conceals the Drug Administration to its medicine unqualified numerous announcements.　　So while the company has been successful, it is still stuck.　　On behalf of shareholders in doubt Asia-Pacific pharmaceutical Industry planning the listing process can be traced back to the 2001 restructuring. Company prospectus shows that December 31, 2001, by the Zhejiang Provincial People's government enterprise listing work leading group listed in Zhejiang [2001]128 approved by Zhejiang Asia-Pacific Group Co., Ltd., Shaoxing County Full Trade Co., Ltd., China Pharmaceutical group Shanghai Company,　　Zhejiang Rongsheng Construction and Development Co., Ltd. and Shaoxing County Li Sheng Materials Co., Ltd. and other 5 legal persons jointly initiated the establishment of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd., the establishment of the registered capital of 60 million yuan. 2000 to 2001 is the start of the start-up board in full swing, the Asia-Pacific pharmaceutical industry at this time restructuring, in the analyst seems to be aimed at the gem. "The emergence of the Chinese pharmaceutical Group, the Shanghai Company, was a testament to the market's impulse," he said.　　"it says.　　When the Asia-Pacific pharmaceutical Industry was established, the Shanghai Company of China Pharmaceutical Group invested 6 million yuan in monetary capital, holding 6 million shares, accounting for 10% of the company's total equity. However, according to the Asia-Pacific pharmaceutical prospectus, the Chinese pharmaceutical group Shanghai Company is actually only on behalf of the actual control of Chen Root holdings, the Chinese Medicine Group Shanghai Company to subscribe to the company's shares of the 6 million Yuan, the Department of Chen in advance into the Chinese Medicine group Shanghai Company account,　　Then the Chinese medicine group Shanghai Company Chen to subscribe to the company 6 million shares. Until April 15, 2005, the Chinese Medicine group Shanghai Company Chen its 6 million shares of the company, all the original price transfer to Chen real control of the Asia-Pacific real Estate, and the Asia-Pacific real estate is directly to Chen Mr. Root paid the equity transfer.　　At the beginning of the preparation of the listing July 30, 2008, China Pharmaceutical Group Corporation also confirmed the relationship between the shares. Just since Chen own funds, why to have a lot of trouble to ask the Chinese medicine group Shanghai Company Holdings? In this respect, the Asia-Pacific Pharmaceutical company Board of directors staff yesterday said in an interview, when the company just set up, and the Chinese medicine group as a large state-owned enterprises, but also China's largest pharmaceutical group, whether resources or experience are very rich, so conducive to the development of the company. "The company should have taken this into account at the time, but the company did not have business dealings with the Chinese pharmaceutical group."　　The official said to the reporter at last.　　But if the gem is successfully opened in the millennium, the Asia-Pacific pharmaceutical industry was the first to hit the gem success, this part of the generation of shareholding in the end?　　Product unqualified six times "conceal"? The main concern for the Asia-Pacific pharmaceutical industry is that it has not disclosed in the prospectus that its drugs have been used by the state and local Food and Drug Administration"Exposure" problem.　　Consult the national and local Food and Drug Administration, at least in 6 cases. The first issue of the National Drug Quality Bulletin of 2002 showed that in the fourth quarter of 2001, 49 production units produced (or formulated) 44 kinds of medicines, 90 batches of which were inferior drugs, including "roxithromycin capsules produced by Zhejiang Asia-Pacific Pharmaceutical factory with a batch number of 010208" Zhejiang Province, the 3rd phase of the 2003 Drug Quality Inspection Bulletin, the batch number 030304 of roxithromycin capsules dissolution unqualified; Hebei Province released the first phase of the 2007 list of substandard drugs, including Asia-Pacific pharmaceutical production of 060703 batches of injection cefoperazone sodium sulbactam Sodium　　, Jiangsu Provincial Food and Drug Administration in 2007, the 1th issue of Drug Quality Bulletin, Asia-Pacific pharmaceutical production of the injection of ribavirin is also listed, because the solution of the clarity and color unqualified. The above five cases are relatively long, but in 2009, the Asia-Pacific pharmaceutical industry also had two cases of "exposure" issues. First, Jiangsu Province Food and Drug Administration issued the 1th phase of the 2009 drug Quality Bulletin, the Asia-Pacific pharmaceutical production of injection cefoperazone sodium and sulbactam sodium solution to the clarity and color visible foreign bodies.　　The second is the Guangdong Provincial Drug Supervision Bureau announced in 2009 the Asia-Pacific pharmaceutical production of 080202 batches of roxithromycin unqualified. It is not mentioned in the prospectus by the pharmaceutical regulatory authorities. In the last three years the company was subject to administrative penalties, the Asia-Pacific pharmaceutical Industry said, "in July 2006, the Wuhan Food and Drug Administration of the company in violation of drug management related regulations, the company fined 31,000 yuan." "But the Asia-Pacific pharmaceutical industry in this explanation is," the company was the punishment, mainly because the distributor of the drug in the custody of the poor due to the drug production process is not a quality problem. "In addition, the prospectus also said, July 14, 2009, Shaoxing County Food and Drug Administration confirmed that Asia-Pacific pharmaceutical Industry" since its inception are strictly in accordance with the provisions of food and drug supervision and management laws and regulations and regulatory documents stipulated in accordance with the law of production and operation, there is no drug quality accidents, there is no intentional　　The case of inferior medicine ". In the case of substandard drugs, the company staff interviewed by reporters said the drug's reserve requirements were high.　　And in the circulation field, affected by some external factors, such as typhoons, temperature, etc., it is easy to lead to product quality problems. But since there are cases where local and national drug administrations have been advertised, only one case of Wuhan can be mentioned in the prospectus, but no mention has been made of other announcements.　　Even in the last year's Guangdong Food and Drug Administration Bulletin, and Jiangsu Provincial Drug Administration Bulletin of the injection cefoperazone sodium sulbactam sodium and the destruction of the resulting losses, the Asia-Pacific pharmaceutical industry in the prospectus did not disclose. "The company's information disclosure is too irregular, which may be the reason for the company after the meeting jam."　　The analyst said to reporters. "The drug was inspected by the FDAUnqualified, responsibility no matter in who, but the enterprise has had the ' list ' experience, the final treatment and how to share the relevant costs with the channel, which is also a major business risk of pharmaceutical enterprises, should have sufficient disclosure. "Some brokerage bankers think.